Pentapharm
Private Company
Funding information not available
Overview
Pentapharm is a long-established, specialized player in the hemostasis and thrombosis space, leveraging deep expertise in the ultra-purification of proteins from natural sources. The company operates a dual business model, supplying high-quality APIs to pharmaceutical companies and critical reagents/kits to the diagnostics industry, supported by strong regulatory certifications. Recently divested from DSM-Firmenich and backed by private equity, Pentapharm is now an independent entity positioned to capitalize on its niche expertise and accelerate innovation.
Technology Platform
Extraction, isolation, and ultra-purification of bioactive proteins and enzymes from natural sources (especially snake venom), integrated with synthetic peptide chemistry for substrates and inhibitors. Platform enables production of APIs for therapeutics and critical reagents for diagnostics in hemostasis.
Opportunities
Risk Factors
Competitive Landscape
Pentapharm competes in specialized niches within the hemostasis market. For APIs, it faces competition from other biological API manufacturers and generic producers. In diagnostics, it competes with large IVD companies (e.g., Siemens, Werfen) and specialized reagent suppliers. Its deep, vertically integrated expertise in venom-derived proteins and long-held regulatory filings create significant barriers to entry and a defensible competitive position.